Tumor-bearing mouse models show that combined treatment with TGF-β inhibition and immune checkpoint antibodies such as anti-PD-L1 were able to induce better tumor regression and more prolonged survival (42, 99), leading the way to combining TGF-β inhibitors with ICB drugs clinically for advanced cancer patients. Here, TGFB1 is linked to neoplasm.